A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study

Background. Immunoglobulin A nephropathy (IgAN) is the most common form of glomerulonephritis, and a substantial number of patients succumb to end-stage renal disease (ESRD). However, prediction of the renal outcome in individual patients remains difficult. We have already published a scoring system using the data in a prospective cohort of IgAN patients followed up from 1995 to 2002. Methods. The cohort was further followed up until 2005 in 97 clinical units in Japan. The data from 2283 patients were analysed by Cox regression to determine the predictors of ESRD in IgAN, and their β-coefficients were converted into scores to estimate ESRD risk within 10 years. Results. During the follow-up (median, 87 months), 252 patients developed ESRD. Male sex, age less than 30 years, family histories of chronic renal failure and chronic glomerulonephritis, hypertension, proteinuria, mild haematuria, hypoalbuminaemia, low glomerular filtration rate and a high histological grade at initial renal biopsy were associated with the risk of ESRD in the multivariable analysis. A scoring system was framed to estimate the 10-year ESRD risk using eight variables significant in both univariable and multivariable models. This prognostic score accurately classified patients by risk: patients with estimates of 0–4.9, 5.0–19.9, 20.0–49.9 and 50.0–100% had an observed incidence of 1.7, 8.3, 36.7 and 85.5%, respectively. The corresponding area under the receiver-operating characteristic curve was 0.942 (95% confidence interval, 0.925–0.958). Conclusion. This validated scoring system to quantitatively estimate ESRD risk during the 10-year follow-up of IgAN patients will serve as a useful prognostic tool in clinical practice.

[1]  O. Kardaun,et al.  Toward individual prognosis of IgA nephropathy. , 1986, Kidney international.

[2]  B. Julian,et al.  Angiotensin converting enzyme gene polymorphism: potential silencer motif and impact on progression in IgA nephropathy. , 1996, Kidney international.

[3]  S. Lemeshow,et al.  Mortality Probability Models (MPM II) based on an international cohort of intensive care unit patients. , 1993, JAMA.

[4]  Y. Yamaji,et al.  Angiotensin-converting-enzyme inhibitors slow renal decline in IgA nephropathy, independent of tubulointerstitial fibrosis at presentation. , 2005, QJM : monthly journal of the Association of Physicians.

[5]  D. Cattran,et al.  Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin a nephropathy: a comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  F. Guillemin,et al.  Polymorphism of angiotensin converting enzyme, angiotensinogen, and angiotensin II type 1 receptor genes and end-stage renal failure in IgA nephropathy: IGARAS--a study of 274 Men. , 2000, Journal of the American Society of Nephrology : JASN.

[7]  M. Lam,et al.  A family-based association study of megsin A23167G polymorphism with susceptibility and progression of IgA nephropathy in a Chinese population. , 2006, Clinical nephrology.

[8]  A. Tamakoshi,et al.  Significance of urinalysis for subsequent kidney and urinary tract disorders in mass screening of adults. , 1995, Internal medicine.

[9]  J. Connell,et al.  Polymorphisms in angiotensin-converting-enzyme gene and progression of IgA nephropathy , 1995, The Lancet.

[10]  Zhi-Hong Liu,et al.  Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies. , 2004, Kidney international.

[11]  K. Thai,et al.  Association of angiotensinogen gene T235 variant with progression of immunoglobin A nephropathy in Caucasian patients. , 1997, The Journal of clinical investigation.

[12]  C. Ponticelli,et al.  Long-term follow-up of IgA mesangial nephropathy: clinico-histological study in 374 patients. , 1987, Seminars in nephrology.

[13]  Yasuhiko Tomino,et al.  Revised equations for estimated GFR from serum creatinine in Japan. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[14]  F. Schena,et al.  Increased risk of end-stage renal disease in familial IgA nephropathy. , 2002, Journal of the American Society of Nephrology : JASN.

[15]  L. Gesualdo,et al.  ACE gene polymorphism and IgA nephropathy: an ethnically homogeneous study and a meta-analysis. , 2001, Kidney international.

[16]  K. Chow,et al.  Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  J. Berger,et al.  [Intercapillary deposits of IgA-IgG]. , 1968, Journal d'urologie et de nephrologie.

[18]  R. Nieuwland,et al.  Plasma markers of coagulation and endothelial activation in Fabry disease: impact of renal impairment. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[19]  É. Renoult,et al.  IgA nephropathy: prognostic classification of end-stage renal failure. L'Association des Néphrologues de l'Est. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[20]  G. D'Amico,et al.  Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[21]  M. Arakawa,et al.  Clinical guidelines of IgA nephropathy. , 1995, Nihon Jinzo Gakkai shi.

[22]  Y. Taguma,et al.  Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[23]  I. Narita,et al.  The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. , 2003, Kidney international.

[24]  A. Tamakoshi,et al.  A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[25]  F. Berthoux,et al.  Prognostic factors in mesangial IgA glomerulonephritis: an extensive study with univariate and multivariate analyses. , 1991, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[26]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[27]  E. Morales,et al.  Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. , 2003, Journal of the American Society of Nephrology : JASN.

[28]  P. Zucchelli,et al.  [IgA nephropathy]. , 1985, Medicina clinica.

[29]  J. Craig,et al.  Immunosuppressive agents for treating IgA nephropathy. , 2003, The Cochrane database of systematic reviews.

[30]  C. Charasse,et al.  Epidemiologic data of primary glomerular diseases in western France. , 2004, Kidney international.

[31]  G. Maschio,et al.  ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: a multicentre, randomized, placebo-controlled study. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[32]  F. Scolari,et al.  IgA nephropathy: the presence of familial disease does not confer an increased risk for progression. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.